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Immunosuppression broadens evolutionary
pathways to drug resistance and treatment failure
during Acinetobacter baumannii pneumonia in mice

Wenwen Huo 1,8, Lindsay M. Busch1,6,8, Juan Hernandez-Bird1, Efrat Hamami1,
Christopher W. Marshall2,7, Edward Geisinger 3, Vaughn S. Cooper 2, Tim van Opijnen
Jason W. Rosch 5 and Ralph R. Isberg 1 ✉

,

4

Acinetobacter baumannii is increasingly refractory to antibiotic treatment in healthcare settings. As is true of most human
pathogens, the genetic path to antimicrobial resistance (AMR) and the role that the immune system plays in modulating AMR
during disease are poorly understood. Here we reproduced several routes to fluoroquinolone resistance, performing evolution
experiments using sequential lung infections in mice that are replete with or depleted of neutrophils, providing two key insights
into the evolution of drug resistance. First, neutropenic hosts acted as reservoirs for the accumulation of drug resistance during
drug treatment. Selection for variants with altered drug sensitivity profiles arose readily in the absence of neutrophils, while
immunocompetent animals restricted the appearance of these variants. Secondly, antibiotic treatment failure in the immunocompromised host was shown to occur without clinically defined resistance, an unexpected result that provides a model for how
antibiotic failure occurs clinically in the absence of AMR. The genetic mechanism underlying both these results is initiated by
mutations activating the drug egress pump regulator AdeL, which drives persistence in the presence of antibiotic. Therefore,
antibiotic persistence mutations present a two-pronged risk during disease, causing drug treatment failure in the immunocompromised host while simultaneously increasing the emergence of high-level AMR.

A

cinetobacter baumannii is a Gram-negative opportunistic
pathogen, one of the high-priority ESKAPE (Enterococcus
faecium, Staphylococcus aureus, Klebsiella pneumoniae,
Acinetobacter baumannii, Pseudomonas aeruginosa, and
Enterobacter spp.) organisms that are increasingly difficult to treat
due to multiple antibiotic resistance1. A substantial proportion of
healthcare-associated diseases caused by this group of pathogens,
such as ventilator-associated pneumonia, is linked to their documented multidrug resistance (MDR)2–5. Of particular importance
are patients in intensive care units who are critically ill and have
depressed immunological clearance mechanisms that increase the
risk of infection by MDR pathogens6,7. Consequently, the healthcare
environment with its immunologically compromised patients could
provide a unique niche for selection of MDR isolates8. Overlaying
these issues is the fact that for many patients in healthcare settings,
antibiotic treatment failure is common but is often unexplained, as
resistant organisms cannot be identified9.
A. baumannii clinical isolates have demonstrated a remarkable
ability to successfully battle antibiotic treatment in the clinic due
to high intrinsic resistance to antimicrobials and the acquisition
of drug resistance elements by the organism10–13. A critical missing
link is a detailed roadmap for the stepwise evolution of antibiotic
resistance in the clinic, particularly in identifying A. baumannii
subpopulations most likely to give rise to drug treatment failure.
Furthermore, it is largely unknown whether there exists a patient

group that provides the reservoir for antimicrobial resistance
(AMR) acquisition. Particularly for healthcare-associated diseases,
patient groups susceptible to A. baumannii are by their nature compromised in several ways, with the potential for providing reservoirs
for AMR evolution. The range of individuals with altered immune
function in these settings may allow for a diversity of host targets
that can act as primary amplifiers of resistance, with eventual spread
to individuals with different sets of susceptibilities. Therefore, as a
model for healthcare-associated pneumonia, we aimed to explore
whether depletion of a single arm of innate immunity in mice could
help shape the antibiotic treatment outcome and support the evolution of resistant organisms.
Fluoroquinolones (FQ) such as ciprofloxacin initially showed
excellent activity against A. baumannii infections14. Members of
this drug class inhibit bacterial cell growth by covalently linking to
DNA gyrase (gyrA) and topoisomerase IV (parC), leading to double
stranded DNA breaks and cell death15. Drug-resistant mutants arise
fairly frequently in the clinic, with over 80% of clinical isolates of
A. baumannii currently being FQ resistant16. The most commonly
reported mechanisms of ciprofloxacin resistance in the clinic are
target protein alterations and the overexpression of efflux pumps.
In A. baumannii, alterations in target proteins usually evolve in a
stepwise fashion, starting with gyrA (usually Ser81Leu) followed by
parC (usually Ser83Leu). Interestingly, in addition to the patient’s
underlying condition and hospitalization status, previous exposure
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Fig. 1 | Continuous passaging of A. baumannii in a lung infection model results in early antibiotic failure in neutrophil-depleted mice. a, The 15-passage
strategy using the pneumonia model in both immunocompetent and neutrophil-depleted mice. Neutrophil depletion was induced by two doses of
cyclophosphamide at 72 and 24 h before infection. At the time of infection, A. baumannii ATCC 17978 was oropharyngeally inoculated into mice at
108 c.f.u., and two doses of CIP were administered at 9 and 19 h post infection. All lineages were derived from a single broth-grown culture. At 27 h post
infection, the mice were euthanized, lungs were homogenized and bacteria were plated on LB agar plates. After overnight growth, the bacteria were
collected and 108 c.f.u. used for the next round of infections/passages. OP, oropharyngeal aspiration; IP, intraperitoneal injection; SC, subcutaneous
injection. b, Rapid development of antibiotic failure resulting from passage in the absence of neutrophils. After lungs were homogenized, total c.f.u. on
LB agar in the absence of antibiotic were determined and plotted as a function of passage number. Shown are three lineages for immunocompetent and
neutrophil-depleted animals treated with CIP as described in a. Illustrations in a were created with BioRender.com.

to fluoroquinolones is also a risk factor for A. baumannii colonization and infection17, indicating that resistance to this antibiotic class
is linked to either increased pathogenic potential of the isolate or
acquisition of MDR. It is unknown whether there exist early adaptive mutations that enable precursor populations of A. baumannii to
act as ancestors of drug resistance.
There has been limited study of whether AMR can be suppressed
by the immune response. Landmark mathematical modelling work
argues that the immune response can largely limit the outgrowth of

persisters or other bacterial variants that exhibit intermediate resistance levels18. Another study indicates that the cytokine response
may control waves of AMR variants19. Given the limited analysis
of how antibiotic resistance evolves in the clinic, and the lack of a
detailed interrogation of the role played by the immune response
in controlling selection of AMR, we sought to identify the steps
that lead to resistance in the presence or absence of a single arm of
innate immunity. The rationale behind this approach is that clinical antibiotic resistance is associated with mutations located outside

Nature Microbiology | VOL 7 | June 2022 | 796–809 | www.nature.com/naturemicrobiology

797

Articles

NATuRE MicRobioLogy

well-characterized drug targets, and these mutations are difficult to
identify bioinformatically or predict on the basis of culture studies20–22. This approach provides evidence that absence of neutrophil
function allows outgrowth of drug persisters and the appearance of
fluoroquinolone resistance. In so doing, we identified mutational
pathways to drug resistance, with the results tied to the problem of
unexplained antibiotic treatment failure.

Results

Recapitulation of A. baumannii evolved drug resistance. We serially passaged A. baumannii 15 times within a mouse pneumonia
model to analyse the dynamics and genetic trajectories of resistance to the FQ antibiotic ciprofloxacin (CIP), with the purpose of
determining whether neutrophils play a role in suppressing drug
resistance (Fig. 1a). The CIPS (ciprofloxacin susceptible) ATCC
reference strain 17978 (AB17978) was passaged by oropharyngeal
inoculation in either immunocompetent animals or those depleted
of neutrophils by pretreatment with two doses of cyclophosphamide. It should be noted that this treatment also has other effects
on the immune system, including the possible reduction of monocyte populations, as well as suppressing T-cell numbers23,24. Mice in
three parallel lineages were CIP treated at 7 and 19 h post infection
(hpi) and bacteria were collected from the lungs of animals euthanized at 27 hpi. The enriched bacterial pools from each independent
infection were used as inocula for the next round of infection. The
dynamics of bacterial yield was assessed from lung homogenates,
and the CIP minimum inhibitory concentration (MIC) of each population was determined, followed by whole-genome sequencing of
the heterogenous pool (mean genome coverage depth: 368.4).
Persistent neutropenia results in treatment failure. A striking result from the passage experiments is that the protocol
allowed drug-resistant mutants to overgrow during passage in
neutrophil-depleted animals, while the resistant variants in the
immunocompetent animal failed to reach high abundance in the
population. After each mouse passage in the presence of CIP, the
efficiency of bacterial colonization of the lungs was monitored
by quantifying total bacterial colony forming units (c.f.u.) in the
absence of the drug. Bacterial lung yields increased by 1,000-fold
in CIP-treated neutrophil-depleted mice over the course of 15
passages, as compared with little increase in immunocompetent
mice (Fig. 1b). After each passage, we observed 10-fold higher
colonization in the neutrophil-depleted compared with immunocompetent mice. By passages 5–7, the lung bacterial load in the
neutrophil-depleted mice reached the size of the initial inoculum
(108 c.f.u.), and animals showed substantial signs of disease, such as
lacrimation, piloerection and decreased mobility, despite being CIP
treated (Fig. 1b).
To determine levels of CIP resistance after each passage, the
saved bacteria were quantified on solid medium in the absence or
presence of increasing amounts of drug, plotting the fraction of
surviving c.f.u. as a function of CIP concentration (Materials and
Methods; Fig. 2a,c). Clinically resistant bacteria (CIP ≥ 2 ug ml−1)

did not arise in the three lineages passaged in immunocompetent mice. Furthermore, the number of bacteria able to survive on
increased amounts of CIP relative to the parental strain never rose
above 0.1% of the population (survival on solid medium containing
1 ug ml−1 CIP). Therefore, in immunocompetent mice, 15 passages
were insufficient to allow outgrowth and fixation of resistant variants in the population.
The evolutionary trajectories through neutrophil-depleted
mice contrasted strongly with those in immunocompetent mice,
as the whole population in all three lineages became CIP resistant
over the course of 15 passages in the former. Bacteria resistant to
at least 2 μg ml−1 CIP were observed as early as the 3rd passage
(Fig. 2c). After the 9th passage, approximately 1 × 10−5 of the bacteria isolated from the neutrophil-depleted mice showed resistance to 8 μg ml−1 CIP, four times higher than the clinically defined
resistance breakpoint. By 15 passages, almost all bacteria from the
neutrophil-depleted lineages were clinically defined as CIP resistant
(at concentration of at least 2 μg ml−1), with a large fraction showing
resistance to CIP = 8 μg ml−1. Therefore, resistance acquisition during disease is amplified in the absence of neutrophils.
Clinical failure from drug-sensitive bacteria. By the 6th passage
in neutrophil-depleted mice, yields of bacteria began to approach
those observed in the absence of antibiotic (Fig. 1b), even though
the majority of the population remained sensitive to CIP based
on the defined clinical breakpoint (Fig. 2c; clinical breakpoint
CIP > 2 μg ml−1). Yields remained high in successive passages, while
the distribution of the population increasingly skewed towards
variants with increasing levels of resistance to CIP. Therefore, drug
treatment failure at passage 6 under neutrophil-depleted conditions
was dominated by bacteria that grew at 1 μg ml−1 CIP but showed
low viability at the 2 μg ml−1 clinical breakpoint. These mutants were
replaced by more resistant isolates during later passages (Fig. 2c).
To link specific mutational changes over time to these observed
phenotypes, we sequenced the pools of genomic DNA (gDNA) isolated from the original inoculum, the parent AB17978 strain, and
the pools collected after the 3rd, 6th, 9th, 12th and 15th passages.
Mutation frequencies were then plotted for each passage in the two
immune conditions (Fig. 2b,d). On the basis of the predicted sensitivity from the depth of pooled whole-genome sequencing, we expected
that only nucleotide changes in greater than 5% of the population
could be detected using this approach (Materials and Methods).
The results from the pooled genomic sequencing allowed us to
identify changes associated with either the development of drug
resistance, or the lack thereof, in these populations. As predicted
from Fig. 2a and the sensitivity limits of the analysis, there was no
evidence for mutations driving drug resistance at greater than 5%
abundance in the three populations evolved in immunocompetent
mice. The only alteration that approached fixation was a mutation in a gene encoding a putative solanesyl diphosphate synthase
(ACX60_03850; ispB), but this allele was unrelated to resistance, as
single colony isolates showed no increased survival in the presence
of CIP (Fig. 2e). All the other mutations identified by sequencing

Fig. 2 | High-level ciprofloxacin resistance evolves in a stepwise fashion during passage in neutrophil-depleted mice. a,c, After each passage, bacteria
from lung homogenates were serially diluted onto LB agar containing noted concentrations of CIP (μg ml−1). The fraction of c.f.u. on the series of CIP
plates was determined for each pool and displayed in stacked bar plots for immune competent (a) and immune depleted (c) mouse infection lineages.
The limit of detection was 2.7 × 10−6. b,d, The gDNA from each bacterial pool was isolated and subjected to whole-genome sequencing to identify the
genomic mutations acquired throughout passaging (after passages 3, 6, 9, 12 and 15). The mutations were detected using a 5% abundance cut-off and
filtered against the parent strain AB17978. The relative abundance of each mutation was plotted as a function of passage number from immune competent
lineages (b) and immune deficient lineages (d). e,f, After 10 or 15 passages (as noted), the bacterial pools from each lineage were incubated on LB in
the presence or absence of CIP (1 μg ml−1) to select for single colonies. Purified single colonies were subjected to whole-genome sequencing and MIC
assays. Each column represents a single colony. Rows display absence or presence of selection criteria, passage, amino acid or SNP (single nucleotide
polymorphism) alleles, and MIC values for each single colony isolate. The presence of each mutation in an individual colony is highlighted in purple. MICs
are labelled and colour-coded for all colonies, and at least 3 biological replicates were performed.
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arose in lineage 2, this mutant being outcompeted by a strain with
multiple genetic alterations, while a quadruple mutant appeared to
overgrow the single adeL mutant in lineage 3.
To identify the various genotypes linked to increased CIP resistance, we isolated single colonies after 9 passages to verify that two
transiently predominant variants had the predicted genotypes,
and also sequenced isolates from passage 15 after plating in the
absence or presence of CIP (1 µg ml−1). Isolated colonies in the
absence of drug selection from lineages 2 and 3 from passage 9
showed the predicted adeL alleles (compare Fig. 2d and f). In addition, after plating the passage 15 pools in the absence of the drug,
the two predicted gyrase alleles gyrA(A117E) and gyrB(Q447H)
that are observed infrequently in the clinic were also identified
(Fig. 2f). Having gyrA(A117E) alone was able to raise the CIP MIC
by 16-fold (Fig. 2f). Clones having the gyrB(Q447H) allele were

Mean fold change
against AB17978

the pools appeared unrelated to resistance, as none survived
incubation on solid medium containing 1 μg ml−1 CIP (Fig. 2b,e).
Furthermore, the analysis of individual colonies isolated after plating bacterial populations on antibiotic-free medium after the 15th
mouse passage identified isolates with CIP MICs that were only
slightly elevated relative to that of wild type (WT) (Fig. 2e, left
panel; WT MIC = 0.25–0.5).
Variants with altered CIP sensitivity arose in the immunocompetent mice, but they remained at low levels in these populations, as predicted by the previous mathematical modelling study
(Fig. 2a)18. Mutations causing decreased drug sensitivity were
identified by isolating single colonies on solid medium containing 1 μg ml−1 CIP, and all 12 of the single colonies selected from the
10th passage had the identical mutation in adeL, the regulator of the
AdeFGH egress pump25,26. The presence of the mutation in multiple
lineages is consistent with its existence in the initial bacterial culture before the first inoculation of all three lineages. Interestingly,
8 distinguishable lineage-specific mutations were identified, these
mutations being derived from the parental adeL(C312*) mutation, consistent with downstream mutations arising during mouse
passage (Fig. 2e, right panel). These strains appeared to have been
largely lost by passage 15 in the immunocompetent mice (Fig. 2a,e).
We conclude that although strains with mutations that activate the
AdeFGH egress pump are detected, they are unable to overgrow the
WT and are eventually depleted during later passages in immunocompetent mice (Fig. 2b).
Consistent with the dynamic nature of resistance acquisition
in neutrophil-depleted mice (Fig. 2b), pool sequencing uncovered
mutations that drove the stepwise trajectory to CIPR (ciprofloxacin
resistant) in later passages (Fig. 2d). Unlike the immunocompetent
lineages, first-step mutations that occurred within adeL after 6 passages in neutrophil-depleted mice were easily detected by whole
pool sequencing. Each lineage harboured different adeL mutations
in these early passages, these mutations disrupting the 3’ end of
the gene, consistent with previous work arguing that alterations in
the C terminus of the AdeL protein result in AdeFGH pump activation25,26. Mutations in various other genomic sites arose between
passages 9 and 12, with many predicted to contribute to decreased
susceptibility to CIP treatment. For instance, the adeL(C312*)
mutant acquired a second mutation in gyrB that overgrew lineage 1.
In addition, a mutant harbouring a non-canonical mutation in gyrA

Time (h)
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only observed to be linked to adeL(C312*) at passage 15, resulting
in a CIP MIC that was 8-fold higher than that of the parent strain
(Fig. 2e). Besides the mutations in target proteins, other single colonies that resulted in a similar MIC increase were found to have
a combination of four mutations (Fig. 2f). When comparing the
isolated single colonies that had a CIP of 1 μg ml−1 to those isolated
without antibiotic, the single colony isolates had genomic changes
that were predicted by the sequencing of the pools, indicating that
the mutants described here became predominant without requiring CIP selection ex vivo.
Mutations in adeL allow for antibiotic persistence. To deconvolve the function of the various mutations observed, we backcrossed mutations into the parent strain and assessed their relative
contributions to CIP resistance. Of particular interest were adeL
nucleotide changes identified in populations after the 6th passage
in neutrophil-depleted mouse lineages, as CIP failed to efficiently
restrict growth in the lung in these passages (Figs. 1a and 2d). The
adeL gene (ACX60_06025)26 has two predicted domains often associated with LysR-type transcriptional regulators: a helix-turn-helix
(HTH) domain and a substrate binding domain responsible for
regulation of the AdeFGH pump (Fig. 3a). Of the adeL mutations
that arose during the in vivo passages, one is located within the
predicted substrate binding domain, while the others are at the
C-terminal end comprising in-frame deletions or early termination

codons (Fig. 3a,b). We constructed strains with each of these mutations and observed 100–1,000× increased adeG transcription levels
compared with the parental strain, consistent with AdeFGH efflux
pump overexpression (Fig. 3c).
While these single adeL mutations resulted in an increase in MIC to
~1 μg ml−1 CIP, which barely rose to the level of significance (Fig. 4c),
this level was below the recognized clinical breakpoint27, and such
strains would be indicated as susceptible. As these are first-step
mutations, we hypothesize that variants harbouring these changes
may facilitate the outgrowth of more resistant isolates by promoting
tolerance or persistence in the presence of antibiotic. To test this
model, we evaluated the survival of adeL mutants during exposure to high levels of CIP28–32. Exposure to 10 μg ml−1 CIP, roughly
20× the MIC of the parental strain, led to the majority of the adeL
mutants (>99%; MDK99) being rapidly killed (within 1 h), mimicking what was observed for the parental strain (Fig. 3d). However,
unlike the parental strain, a subpopulation of the adeL mutant was
able to persist through 24 h of drug exposure (Fig. 3d). This phenotype was dependent on pump overproduction, as an adeL mutant
strain deleted for the adeFGH operon was indistinguishable from
the parental strain in regards to persistence (Fig. 3d). These data
argue that adeL mutations drive persistence in the presence of CIP
via increased expression of adeFGH, providing a reservoir within
neutrophil-depleted animals for the outgrowth of strains with
increased resistance33.
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Resistance can be explained by adeL combined with mfsA. We
continued backcross analysis to identify the minimal determinants
necessary to confer clinical resistance during passage in the mouse.
Many of the single colony isolates from lineage 3 at passage 15 of the
immunocompromised mice possessed a combination of mutations
in four genomic locations: adeL, acfR (ACX60_03155), lpxD and
the intergenic rpmL-mfsA region, the latter being located between
a ribosomal protein gene and a predicted coding region for a putative MFS transporter, which we have named mfsA (ACX60_15150,
annotated as nreB in GenBank; Fig. 2d,e). To determine the role of
each of these mutations in drug susceptibility, we constructed separate strains carrying single mutations. All single mutants showed
various MICs well below 2 μg ml−1 CIP, with each of the adeL
mutations as well as mfsA(−9) showing increased MICs above the
parental strain (Supplementary Table 1 and Fig. 4c). The mfsA(−9)
mutation is located 9 bp upstream of a predicted MFS efflux pump,
within 2 bases of a previously reported mutation selected during
evolution of CIP resistance in A. baumannii in planktonic conditions34. Consistent with MFS transporter overproduction, we found
that the mfsA(−9) mutation increased the mfsA mRNA levels
by ~9-fold relative to the parental strain, on the basis of q-rtPCR
analysis (Fig. 4b). Significantly, when the mfsA(−9) mutation was
combined with the adeLP131H mutation, the CIP MIC increased
802

to ~4 ug ml−1, approaching that of the quadruple mutant strain isolated from mouse passage 15 (Fig. 4c and Supplementary Table 1). A
single nucleotide change, located near the mfsA(-9) mutation, that
arose transiently in the immunodepleted lineage 3 (Fig. 2d; mfsA
(-19)) behaved nearly identically (Fig. 4b,c). Therefore, combining
two mutations that resulted in upregulation of both the AdeFGH
pump and a putative MFS transporter was sufficient to provide CIP
resistance above the clinical breakpoint, approaching that seen for
the quadruple mutant.
Mutations in lpxD is linked to fluoroquinolone resistance.
The mutation lpxD(T118_A119insA) (locus tag: ACX60_07955;
GenBank: AKQ26661.1) was consistently found in CIPR isolates
from mice. This alteration within an acyltransferase involved in
lipo-oligosaccharide biosynthesis35–37 showed no effect on MIC
(Supplementary Table 1). To test for clinical linkage of lpxD mutations to drug resistance, we downloaded the genomes of all 8,666
A. baumannii genome clinical isolates from the PATRIC database38.
Focusing on non-repetitive sequences that had antibiotic resistance
profiles, 1,830 were resistant to ciprofloxacin and 215 were susceptible. Of the CIPR isolates, 883 genomes had an E- > K change at
residue number 117, with a z-score ≥ 18 (Extended Data Fig. 1). In
comparison, only 9 of 215 CIPS isolates had the same mutation. By
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Fisher’s exact t-test, P < 0.0001, supporting the significance of these
observations.
To determine whether the overrepresentation of the lpxD(E117K)
allele could be due to outgrowth of a single clone, we performed
multilocus sequence typing (MLST) using the Pasteur A. baumannii scheme, generating 7-gene allele profiles39. Of the 123 distinct
MLST groups, 16 had both CIPR and CIPS isolates (Supplementary
Dataset 1 and Extended Data Fig. 2), although over half of the CIPR
isolates belonged to two MLST types (ST2 and ST3). To avoid skewing the results due to this overrepresentation, we limited the number
of isolates per ST group to 1, reducing strains analysed to 139 across
123 distinct MLST groups (Fig. 5a), including 59 CIPR isolates and
80 CIPS. Even after limiting the clonal effects in this fashion, we still
observed overrepresentation, with the E117K allele found in 13 of
59 CIPR isolates (Fig. 5b), while only 3 of 80 CIPS isolates had the
same alterations (Fig. 5b; P = 0.0011, Fisher’s exact t-test). Both a
whole-genome phylogenetic tree (Extended Data Fig. 3) and clustering analysis of the 7-gene allelic profiles from these 139 clinical
isolates (Fig. 5c) identified CIPR isolates that shared parents with
CIPS ones, further arguing against clonal effects for the enrichment.
Interestingly, the alteration at residue E117 (z-score, 8.98;
P < 0.00001) directly precedes the T118 allele identified in our
mouse experiments, with both variants predicted to be in a turn
between two beta sheets (Fig. 5d; Copyright (2007), National
Academy of Sciences, USA)38. Although the significance of this
linkage is unclear, the fact that the lpxD(T118_A119insA) has a fitness defect in broth (Fig. e) raises the possibility that mutations in
this turn could contribute to a persistence phenomenon in tissues,
leading to evolution of drug resistance.
Evolutionary replay reconstructs drug resistance pathway. The
observation that resistant organisms outcompeted a persistent
strain (Fig. 2d) could be due to a coincidence that occurred during serial passage or due to antibiotic-driven selection for strains
with increased MIC over persistent strains. We performed 3 evolutionary replay experiments40 with neutrophil-depleted lineage
3 variants to distinguish between these possibilities. In the first
(Fig. 6a), bacteria were collected after passage 9 and cycled 3 times
in duplicate in neutrophil-depleted animals to test whether the
adeL(ΔI335A336) allele, a 6-nucleotide in-frame deletion identified in cyclophosphamide-treated animals, would again be outcompeted by low abundance drug-resistant mutants (Fig. 2d). The
second approach was to passage 3 times a mix of a colony-purified
drug-persistent adeL(ΔI335A336) single mutant (P9Cy3.1;
Supplementary Table 1) with a colony-purified drug-resistant quadruple mutant (Cy31; Supplementary Table 1) in the approximate
ratio present at passage 9 (95:5; Fig. 6b). The third was to test the
model that neutrophils restrict the outgrowth of strains having activating mutations in adeL (Fig. 6c).

When the adeL mutant was analysed in competition within the
pool (Fig. 6a) or when mixed 95:5 with colony-purified quadruple
mutant (Fig. 6b), we observed an increase in bacterial burden and
the fraction of bacteria showing CIP MIC > 2 after passaging the
pools in neutrophil-depleted CIP-treated mice (Extended Data
Fig. 4). Whole-genome sequencing of the bacterial populations
collected after each passage revealed a near-identical evolutionary trajectory as seen from the original experiment, with the single
mutant associated with drug persistence eventually outcompeted by
drug-resistant mutants (Fig. 6a–c). Furthermore, in one of our replicate lineages (Fig. 6a), another mutation located in the intergenic
region between rpmL and mfsA (mfsA(-19)) appeared transiently in
immunodepleted lineage 3 (Fig. 2d), further arguing for the contribution of this regulatory region in resistance evolution. Therefore,
these two reconstructions (Fig. 6a,b) demonstrate that the evolutionary trajectory is reproducible, and can be regenerated by phenotypically similar mutations that arise spontaneously.
In the third experiment, single adeL mutants were unable to
overgrow the WT in the presence of CIP in immunocompetent
animals, in contrast to what was observed in passage 9 of the
neutrophil-depleted animals. When a 5:95 (adeL:WT) mixture
was passaged in immunocompetent mice, the mutant was unable
to increase its population share (Fig. 6c), mimicking the failure of
adeL activating mutations to overgrow the pool in any of the immunocompetent lineages (Fig. 2a). In contrast, CIPR mutants having
canonical resistance alleles in gyrA or gyrAparC were able to compete efficiently with WT in the presence of neutrophils, with the
gyrA(S81L) parC(S84L) double mutant growing from 5% to 70% of
the population within 3 passages (Fig. 6c). This argues that depleting the immune response allows the outgrowth of persister mutants,
facilitating complex pathways to drug resistance that are blocked in
immunocompetent hosts.
Ciprofloxacin treatment selects for enhanced fitness. Antibiotic
resistance is often associated with a fitness cost41 that may be compensated over time by continued selection of secondary genotypes
that overcome these costs. The inability of the adeL mutant to overgrow WT during infection in the presence of CIP in immunocompetent animals may reflect this point. Mutants with high resistance,
however, could maintain their selective advantage over non- or
low-resistance mutants even in the absence of drug treatment. To
test this model, the relative fitness of the drug-resistant mutants
derived from neutrophil-depleted lineages was compared to that of
the parent strain AB17978. In the absence of CIP, variants isolated
after passage in neutrophil-depleted mice showed varying degrees
of subtle growth impairment in broth relative to the parental strain
(Fig. 6d; Cy11, P < 0.01). During animal infections in the absence
of antibiotic, these growth defects were amplified. When immunocompetent mice were challenged with the high fitness gyrAparC

Fig. 6 | Fitness advantage in the presence of drug drives evolutionary trajectory. a, An adeL mutant is outcompeted by a quadruple mutant (Cy31)
having drug-resistant adeLmfsA alleles during drug treatment. Passage 9 pool was oropharyngeally inoculated into neutrophil-depleted mice in separate
lineages and passaged 3 times in the presence of CIP. a,b, Plots showing abundance of mutations identified in pools as a function of the passage number.
Strains were mixed at a ratio of 95:5 (single:quadruple mutant), and oropharyngeally inoculated into neutrophil-depleted mice in the presence of CIP.
Deep sequencing was performed to determine the ratio of strains, with abundance of each mutation displayed as a function of passage. c, Presence of
neutrophils prevents enrichment of adeL mutant during CIP challenge. Competition of adeL(ΔI335I336), gyrA(S81L) or gyrA(S81L) parC(S84L) against WT
was performed. Strains were mixed at a ratio of 95:5 (WT:mutant), oropharyngeally inoculated into immunocompetent mice, then passaged in separate
lineages in the presence of CIP. Abundance of each mutant was determined by measuring the colony forming efficiency (CFE) on CIP at a concentration
below the mutant MIC but above that of WT (adeL(ΔI335I336), MIC = 0.75 µg ml−1; gyrA(S81L), MIC = 0.75 µg ml−1; or gyrA(S81L) and parC(S84L),
MIC = 2 µg ml−1). CFE = colonies on antibiotic-containing medium/colonies in the absence of antibiotic, displayed as strain abundance (%). d, Browth
culture growth rates of isolates from mouse passage. Data are mean ± s.e.m. from 3 independent biological replicates. Significance determined by one-way
ANOVA followed by Dunnett’s multiple comparison. **P < 0.01 for Cy11 against WT. C312*, stop codon at residue 312. e,f, Neutrophil-replete (e) and
neutrophil-depleted (f) (cyclophosphamide-treated) BALB/C mice challenged oropharyngeally with noted strains for 24 h to determine the selection rates.
At least 9 independent biological replicates were performed. Data shown are individual datapoints (black), with red bars showing mean ± s.e.m. Statistical
significance was determined by one-way ANOVA followed by Dunnett’s (e) or Tukey’s (f) multiple comparison. *P < 0.05, ****P < 0.0001.
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mutant in competition with WT, the two strains showed similar levels of colonization (Fig. 6e). In contrast, each of the drug-resistant
mutants derived from neutrophil-depleted mice competed poorly
in immunocompetent animals (Fig. 6e; P < 0.0001).
Although the lowered fitness of mutants in immunocompetent
animals further supports the model that outgrowth of unique resistance alleles occurs in the absence of neutrophils, it did not directly
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Cy31 strain had a clear fitness advantage over its predecessor, the
lineage 3 adeL mutant, when competed in the absence of antibiotics (Fig. 6f; Cy31 against P9Cy3.1). Therefore, in competition with
persister mutants, ciprofloxacin simultaneously selected for an isolate with increased CIP resistance and enhanced fitness relative to
mutant competitors. This predicts that drug-resistant mutants can
evolve to heightened fitness to replace persister mutants. As fitness
increases, resistant mutants should be able to compete with sensitive
strains even after cessation of antibiotic treatment, potentially escalating treatment failure and providing fertile ground for the emergence of resistant strains with high fitness.

Discussion

Comparative analyses of bacterial pathogen databases indicate that
clinical antibiotic resistance is associated with mutations located
outside well-characterized drug targets20–22. Analysis of clinical
resistance is often retrospective, with a few exceptional studies that
have allowed identification of a timeline of bacterial resistance in
human populations28–32,42–44. Our study bridges an important gap
in understanding how resistance evolves, by following experimental evolution of fluoroquinolone resistance in a pneumonia disease
model. Strikingly, in the absence of one arm of immune pressure,
A. baumannii resistance arose after few passages in murine lungs
during CIP treatment (Fig. 1b), resulting in treatment failure.
Conversely, the overall frequency remained low in immunocompetent mice, and this did not lead to treatment failure (Fig. 1b).
The absence of neutrophils resulted in the identification of rare
alleles associated with drug resistance. In contrast to the canonical target site gyrA(S81L)parC(S84L) mutant that shows high fitness under conditions tested, the gyrA(A117E) and gyrB(Q447H)
alleles rarely observed in clinical strains predominated in two of
the lineages from neutrophil-depleted animals (Fig. 2e). These
unusual isolates showed fitness defects during disease and/or in
culture (Fig. 6), making them unlikely to arise in the presence of
intact immune functions, consistent with evolutionary trajectories
being determined by the immunological state of the host. Therefore,
we propose that immunocompromised hosts are incubators for
the generation of unique drug-resistant variants, with uncertain
outcomes after pathogen exposure to the community at large.
Although the variants we described have reduced fitness relative to
WT, continued passage demonstrated that stepwise increase in drug
resistance was associated with stepwise increase in fitness (Fig. 6).
Similar fitness effects have been obtained during continued passage
in culture34. The recent demonstration of enhanced viral evolution
of SARS-CoV-2 (the virus that causes COVID-19) in an immunocompromised patient undergoing therapeutic antibody treatment
is a graphic example of the potential interplay between immunity,
antimicrobials and evolution in the clinic, with potential large-scale
community effects45. Furthermore, persistence mutants have been
demonstrated to arise during continued antibiotic therapy in an
immunocompromised patient treated for vancomycin-resistant
enterococcus46, tying the results presented here with documented
clinical outcomes.
Antibiotics primarily act by targeting essential cellular functions
or pathways47,48. In response to transient antibiotic exposure, a proportion of bacteria typically persist or tolerate this treatment, with
mutations arising that can increase the fraction of the surviving
population49–51. The mechanisms for allowing persistence/tolerance
probably differ between bacterial species and vary among antibiotics52, but it is generally agreed that persistence/tolerance is caused by
cell dormancy53–55 or transient expression of efflux pumps and stress
response pathways28,56. Persistence/tolerance mechanisms may play
an important role in the relapse of bacterial infections57–59. In our
study, we found that persistence in A. baumannii can be promoted
by upregulation of a drug efflux pump, AdeFGH26. It is known
that clinical isolates often overproduce efflux pumps that remove

multiple antibiotics from the bacterial cytoplasm26,60, and that antibiotic persistence is associated with such pump upregulation61,62. Of
note, mutations upregulating this pump are rarely isolated in the
laboratory through simple antibiotic single-step selections on solid
agar, indicating that there may be a special environment in the lung
that allows outgrowth of these mutants. It should be noted that all
lineages in both immunocompetent and the immune-depleted mice
were derived from a single bacterial culture. This had the disadvantage of having mutations present in the initial culture to be selected.
It also had the unexpected advantage of demonstrating that a
mutant restricted in immunocompetent mice was able to proliferate
in the absence of neutrophils.
There are three important repercussions from the analysis of
the AdeL efflux overproducer mutations. First, overproduction
results in drug treatment failure during pneumonic disease in the
mouse, even though these bacterial strains are CIP-sensitive based
on the international standard for clinical breakpoints27. Therefore,
clinical drug treatment failure in the absence of identified antibiotic
resistance9 could be explained by the outgrowth of drug-persistent
mutants, particularly in the immunocompromised host. Second,
the adeL mutations provide a molecular basis for A. baumannii
to develop second-step variants that lead to CIP resistance above
the clinical breakpoint. Of interest, inhibitors of efflux pumps have
been suggested to re-sensitize bacteria to multiple antibiotics63, but
such a regimen might also delay progression to resistance. Finally,
isolates from drug treatment failure occurring in immunocompromised patients could generate a pool of precursor mutants giving rise to resistant isolates that eventually infect a broad range of
patients. Several studies have similarly argued that efflux pump
mutations provide a critical pool for the multistep evolution of antibiotic resistance33,64,65
We propose a model of bacterial resistance progression in immunodepleted hosts (Extended Data Fig. 5). When infecting a host,
the antibiotic-susceptible bacteria colonize at a relatively low rate.
With active transmission and continuous CIP treatment, there is
outgrowth of bacterial persisters that have MICs below the clinical
breakpoint, increasing the bacterial load at the infection site. On
continued treatment, or transfer to a similar host undergoing CIP
treatment, fully resistant mutants can then outgrow the population.
The presence of intact immune function interferes with outgrowth
of these mutants, but the identification of persister mutants in the
presence of immune function indicates that such alleles could act
as enablers of drug resistance in all hosts, particularly under conditions of temporary breaching or depression of innate immunity.
Genomic analyses can identify allelic variants linked to drug
resistance, but verifying the functional importance of these alleles
is hindered by founder effects that are often difficult to discount.
The lpxD(E117K) mutation is one such allele associated with resistant gyrA S81L-containing genomes. The fact that the adjacent
lpxD(T118 insA) allele was isolated during multiple passages in
immune-depleted mice argues for a role of these altered residues
in supporting the outgrowth of drug-resistant organisms. The
lpxD(T118 insA) mutation probably alters envelope function. This
raises the possibility that the mutation causes subtle changes in permeability that slow drug access to target, or else the slowed growth
of strains harbouring this allele increases drug tolerance during
growth in tissues52. Our inability to demonstrate increased tolerance
to CIP and the fact that the clinical lpxD(E117K) did not show a fitness defect when grown in LB broth (Fig. 5e) argues that the critical
phenotypes may be observed exclusively during growth in tissues,
making them difficult to evaluate.
In summary, we hypothesize that resistance progression in clinical isolates follows a similar trend witnessed in our experiments,
albeit with greater complexity in the human. Drug-sensitive bacteria may colonize both healthy and immune system-compromised
patients, but resistance evolution occurs more rapidly within hosts
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having impaired neutrophil function. The canonical resistance
mutations that arise within healthy individuals may compete efficiently with host-evolved mutations in patients having impaired
neutrophil function. Hence, the transmission from individuals
having intact immune function may pose risks to immunocompromised patients. Adding to the risks to vulnerable patients, we found
that A. baumannii persistence mutants with MIC levels below the
clinical breakpoint were associated with treatment failure, emphasizing the difficulty in treating these patients (Fig. 1b)9,66–69. While
heterogeneity and variability between infected patients is inevitable, this work provides insight into some genetic factors that could
predispose individuals to treatment failures in specific clinical
contexts. Future work should be focused on how this evolutionary
trend towards drug resistance can be controlled, such as tackling
the molecular basis for selection of persister or other mutations that
lead to treatment failure.

Methods

Use of animals and ethics statement. All animals in the study are
6–8-week-old female BALB/C mice. A sample size of 3 was selected for animal
experiments to minimize the use of animals. Neutrophil depletion procedure
and bacterial infection were performed on randomly selected mice. Use of
immunocompromised animals cannot be blinded as they are readily identified by
their increased lethargy and disease susceptibility relative to untreated animals.
All mice were housed in ventilated caging systems (10–15 air changes per hour) at
temperatures of 68–79 °F (~20–26 °C) and 30–70% humidity, with 12 h light/12 h
dark cycle. All animal procedures were approved by the Institutional Animal
Care and Use Committee (IACUC) of Tufts University. The animal care and use
programme at Tufts University/Tufts Medical Center – Boston Campus has been
continuously accredited by AAALAC since 18 April 1966. The facility maintains
a current USDA research license (14-R-0082) and holds the Public Health Service
Policy Assurance number D16-00459 (A3775-01). The animal care and use
programme maintains compliance with these regulatory bodies.
Bacterial strains. Bacterial strains used in this study are listed in Supplementary
Table 1. A. baumannii strains are derivatives of ATCC 17978. Bacteria were grown
in Lysogeny Broth (LB, BD244620) (10 g l−1 tryptone, 5 g l−1 yeast extract, 10 g l−1
NaCl) or on LB agar plates (LB supplemented with 15 g l−1 agarose, BD214010).
Broth cultures were grown at 37 °C in flasks with orbital shaking at 200 r.p.m.
or in tubes with rotation on a roller drum at 56 r.p.m. Growth was monitored
by measuring absorbance spectrophotometrically at 600 nm (A600nm). Plates
were incubated at 37 °C. Antibiotics were used at the following concentrations:
Gentamicin (Sigma, G3632), 10 μg ml−1 (A. baumannii) and 50 μg ml−1 (Escherichia
coli); Carbenicillin (Sigma, C1389), 100 μg ml−1.
Murine experimental evolution. The in vivo passaging experiments were
performed identically in either immunocompetent or neutrophil-depleted
6–8-week-old female BALB/C mice (Fig. 1a). Neutrophil depletion was induced
via cyclophosphamide pretreatment70. Cyclophosphamide monohydrate at
150 mg kg−1 and 100 mg kg−1 (Sigma-Aldrich: C7397) were administered 4 d and
1 d before infection, respectively. At the time of infection, mice were transiently
anaesthetized by inhalation of isoflurane and lung infections were established
using ~108 colony forming units (c.f.u.) of A. baumannii from mid-log phase
cultures (A600nm ~ 0.5) via oropharyngeal aspiration71. For passage 1, all lineages
were derived from a single broth-grown culture. At 7 and 19 hpi, 100 mg kg−1 of
ciprofloxacin (Sigma-Aldrich, PHR1044) was administered via subcutaneous
injection. At 27 hpi, mice were euthanized, and lungs were removed aseptically
and homogenized in 1 ml of ice-cold 1× phosphate buffered saline (PBS; Thermo
Fisher, 10010049). Afterwards, the homogenate was plated on large (150 ×15 mm)
LB agar plates and incubated for ~17 h at 37 °C. The total number of bacteria was
quantified using c.f.u. The enriched bacteria were scraped off the LB plates and
resuspended in 1× PBS. The resuspension was used for DNA isolation and as
inoculum for the next passage/round of infection (stored at −80 °C in 20% glycerol
before use). For each round of mouse infection/passage, frozen bacterial stocks
were revived by diluting them in LB broth and growing them to exponential phase.
Afterwards, ~108 c.f.u. of the pool was used to establish infection in each mouse.
Three separate lineages of murine infections were maintained in parallel in each
condition (immunocompetent or neutrophil depleted), and within each lineage,
each starting inoculum was passaged 15 times. Validation experiments involving
the reconstruction of identified mutants and re-passaging of these strains in mice
were similarly performed.
Murine competition assays. Competition experiments were performed
following previously published procedures71. Designated strains were grown to
exponential phase (A600nm ~ 0.5–1.0) and mixed at a 1:1 ratio for the inoculum.
Afterwards, ~108 c.f.u. of the bacterial mixture was used to challenge WT or
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cyclophosphamide-treated BALB/C mice via the oropharyngeal route as described
for the mouse passage experiments. At 24 h post inoculation, lungs were removed
aseptically, homogenized and extracts were spread on LB agar plates. To quantify
the input and output ratio of each designated strain, both the inoculum and the
lung homogenate were serially diluted in 1× PBS and plated on LB agar as well as
LB agar supplemented with 2 μg ml−1 ciprofloxacin to differentiate between the WT
and CIP-resistant test strains. Selection rate coefficients (SRC) were determined as
SRC = ln(Strain 1 output/input ratio) – ln(Strain 2 output/input ratio)72. GraphPad
Prism v9 was used for statistical analysis and significance was determined by
one-way analysis of variance (ANOVA) followed by Dunnett’s or Tukey’s multiple
comparison. *P < 0.05, ****P < 0.0001.
Evolutionary replay experiments. For the evolutionary replay experiments
(Fig. 6a), the saved Cy3 passage 9 pool was used as inoculum. For the evolution
experiments involving isolates (Fig. 6b,c), designated strains were grown to
exponential phase and mixed at a 5:95 ratio in the inoculum. In both cases, the
inoculum was administered via the oropharyngeal route and passaged three times
in the presence of CIP treatment in a near-identical manner as the initial passaging
experiments. Each pool/mixture was performed in duplicate. The bacterial pools
after each passage were saved, and variant frequencies at each passage were
determined as described above. The abundance of each mutant in the isolate
mixtures was determined by measuring the colony forming efficiency (CFE) at
an antibiotic concentration that was below the mutant MIC but above that of WT
AB17978. The CFE versus passage number was displayed and expressed as strain
abundance (%). CFE = number of colonies on antibiotic-containing medium/
number of colonies in the absence of antibiotic.
Determining resistance as a function of drug concentration. For each passage,
to evaluate the fraction of bacteria that are viable on culturing in various
concentrations of ciprofloxacin, the glycerol stock of each pool was revived in
fresh LB broth and grown to exponential phase. A total of ~107 c.f.u. was used for
serial dilutions in 1× PBS and 10 μl from each diluted culture was spotted on LB
agar plates containing the following concentrations of ciprofloxacin: 0, 0.25, 0.5, 1,
2, 4 and 8 μg ml−1. After an overnight incubation at 37 °C, colonies were counted,
and c.f.u. per ml was calculated. A detection limit of 100 c.f.u. ml−1 was used. The
fraction of bacteria resistant to a certain concentration (C0; C0 > 0) of ciprofloxacin
was calculated as (c.f.u. ml−1 at C0 − c.f.u. ml−1 at all concentrations above C0) / Total
c.f.u. A stacked bar plot of the data was generated using GraphPad Prism (Fig. 2).
Whole-genome sequencing. Genomic DNA was extracted from bacteria
using the DNeasy blood and tissue kit (Qiagen, 69506). Library preparation
was performed using Illumina Nextera73. For each sample, 7 ng of gDNA was
fragmented using Illumina Tagment DNA TDE1 enzyme (Illumina, 20034198)
for 5 min at 55 °C. P5 and P7 indices (Illumina FC-131-1002) were then ligated
to the fragments through 8 cycles of PCR (15 s at 98 °C, 30 s at 60 °C, then 1 min
30 s at 72 °C) using EBNext High-Fidelity 2X PCR Master Mix (NEB, M0541S).
The universal sequencing primers (P1: AATGATACGGCGACCACCGA; P2:
CAAGCAGAAGACGGCATACGA) were ligated using 4 cycles of PCR (20 s
at 98 °C, 20 s at 60 °C, then 30 s at 72 °C) using EBNext High-Fidelity 2X PCR
Master Mix (NEB, M0541S). Lastly, the samples were quantified and pooled into
libraries at equal molarity. Libraries were sequenced using HiSeq2500 at Tufts
University Core Facility using single-end 100 bp reads. Reads were aligned to the A.
baumannii ATCC 17978 genome and its plasmids (GenBank Accession: CP012004;
pAB1: CP000522; pAB2: CP00523; pAB3: CP012005), and variants were identified
at 5% cut-off using breseq 0.3274. Reads were aligned to A. baumannii ATCC
17978 reference genome (https://genomes.atcc.org/genomes/e1d18ea4273549a0)
to include an additional 44 kb gene cluster75. The identified mutations are listed in
Supplemental Dataset 2. The predicted functional impact of substitution variants
was determined using PROVEAN76.
Persistence assay. A. baumannii was grown in 3 individual LB broth cultures
overnight from separate colonies. The cultures were diluted 1,000-fold into 8 ml
LB broth and incubated by rotation at 37 °C for 2–3 h until reaching mid or late
exponential growth (A600nm ~ 0.3–0.8). Ciprofloxacin was added to reach a final
concentration of 10 μg ml−1, the concentration regarded as 20× the MIC for the
parent ATCC 17978 A. baumannii strain. These cultures were then incubated
at 37 °C for up to 24 h. After 0, 1, 3, 6 and 24 h, 500 μl of culture was removed,
washed twice in 1× PBS, resuspended in 500 μl PBS and sequentially diluted in 1×
PBS. Serial dilutions were used for c.f.u. quantification by spot plating on LB agar
plates. Dilution factors harbouring quantities ranging from 3–35 c.f.u. were used
to calculate the c.f.u. per ml. The limit of detection by this assay was determined
to be 375 c.f.u. The c.f.u. per ml across the biological replicates at each timepoint
throughout the drug challenge were plotted as mean ± s.e.m.
RT-qPCR gene expression analysis. Bacteria were grown to early stationary
phase in LB broth. RNA was collected and purified using RNeasy kit (Qiagen:
74106), followed by cDNA (complementary DNA) synthesis using SuperScript
VILO cDNA kit (Invitrogen, 11754050). The cDNA was then amplified
with PowerUp SYBR Green Master Mix (Applied Biosystems, A25742) via a
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StepOnePlus Real-Time PCR system (Applied Biosystems, 4376600) following
the manufacturer’s instructions, and target amplification efficiency was evaluated
by generating a standard curve with dilutions of cDNA (>95% amplification
efficiency for each primer pair). Primers were designed to amplify regions of
around 150 bp internal to genes (Supplementary Table 2). Triple technical replicates
were examined per biological sample and at least three biological replicates per
strain were tested, with controls lacking reverse-transcriptase included to verify
a lack of contaminant genomic DNA. Transcript levels of specific targets from
each strain were evaluated by the comparative 2-ΔΔCt method to the parental
strain, normalizing to 2-ΔΔCt value of the endogenous control 16s (16S ribosomal
RNA). The transcript level for each target across biological replicates was plotted
as mean ± s.e.m. (Figs. 3 and 4). When needed, statistical analysis was performed
using two-tailed Student’s t-test against the mean fold change of WT using
GraphPad Prism v9.
MIC determination. MICs were determined by broth microdilution. Overnight
cultures of strains of interest were diluted 1,000× in fresh LB broth and grown to
mid-logarithmic phase (A600 ~ 0.5). Afterwards, cultures were diluted to a final
A600 = 0.003 and tested in the presence of 2-fold dilutions of antibiotics. Culture–
antibiotic mixture (200 μl) was then aliquoted to a 96-well plate (COSTAR) and
technical duplicates were performed in a Biotek plate reader with rotation. Growth
was monitored by measuring A600 at 15 min intervals for 16 h, and the MIC was
determined as the lowest concentration of drug that prevented growth, using
at least three biological replicates for each strain. The MICs across biological
replicates were plotted as mean ± s.e.m. (Fig. 4). Statistical significance was
tested using one-way ANOVA followed by Dunnett’s multiple comparison using
GraphPad Prism v9.
Molecular cloning and mutant construction. Plasmids and primers used in this
study are listed in Supplementary Table 2. The mutant strains were constructed
through sequential cloning into pUC1877 then pJB464878 as previously described13.
Briefly, the mutant allele from each strain of interest was amplified alongside
upstream and downstream segments to generate a PCR product ~1,500 bp in
length flanked by appropriate restriction sites. The PCR product was then ligated
into pUC18 and propagated in E. coli DH5α. The PCR product was then subcloned
from pUC18 into pJB4648 and propagated in E. coli DH5α λpir. After sequence
confirmation, the pJB4648 plasmid construct containing the desired mutation was
introduced into A. baumannii via electroporation. Markerless, in-frame mutations
were isolated via homologous recombination as described13.
Comparative sequence analysis. Genome sequences from 8,666 A. baumannii
clinical isolates and ciprofloxacin resistance profiles for 2,618 isolates were
downloaded from the PATRIC database in November 2021 as described in results.
MLST analysis was performed using Pasteur scheme39 with the publicly available
tool ‘mlst’ (https://github.com/tseemann/mlst). Of the 2618 entries, 2045 were
non-repetitive and with whole genome sequences available. The LpxD protein
sequence from ATCC 17978 was compared to these 2,045 isolates using ‘tblastn’
to identify the amino acid locations of mismatches and gaps. The nucleotide
sequences with the best matches to the LpxD protein were extracted and translated
into protein sequences. For each isolate, the translated LpxD sequence was
compared to the reference LpxD sequence from AB17978. The non-synonymous
changes were recorded for each clinical isolate. The non-synonymous changes at
each residue were then summarized to reflect the total number of clinical isolates
showing those changes. The raw numbers were further transformed into z-scores
to determine whether a particular residue was significantly overrepresented by
non-synonymous changes linked to CIPR or CIPS phenotypes (Extended Data
Fig. 1). To reduce clonal effects, one clinical isolate per ST group was selected
randomly. Multiple aligned LpxD protein sequences are shown in Supplementary
Dataset 3. One isolate had no hit for LpxD. The MLST profiles from 7
housekeeping genes were used to calculate the Euclidean distance, and hierarchical
clustering was determined using R (Fig. 5a). A phylogenetic tree from these
139 genomes was built using mashtree79 and visualized in Geneious Prime
(https://www.geneious.com/) (Extended Data Fig. 3). The presence and absence
of isolates were summarized and visualized in a heatmap using GraphPad Prism
v9 (Fig. 5b and Extended Data Fig. 2). Within each group, the mismatches/gaps
at each amino acid location within LpxD were displayed as number of genomes
having mismatches/gaps at that location. A table of the data was constructed
showing the specific amino acid in the rows, the genome groups harbouring these
mutations in the columns, and the total number of mismatches/gaps in the cells.
The results in each cell were then normalized using z-scores with the mean and
standard deviation from individual genome groups. The z-score was plotted as
function of each residue.
Calculation of doubling time in broth culture. Overnight cultures of bacteria
were diluted 1,000-fold in fresh LB broth and grown for 8 h. The A600 values were
measured every hour using a spectrophotometer, and the log2-transformed values
were plotted as a function
of time (h). To calculate
the doubling time, a modified
(
)
L1
sigmoid function y = −k(x−
− L2 was fitted to the plotted curve (y,
x0 )
e

+1

log2-transformed A600 value; x, time in h; x0, timepoint when the growth rate was

the fastest; k, L1, L2 are rate constants). The fastest growth rate for each culture
was determined as the time in which the second derivative of the fitted curve
approached 0 (or when x = x0), at which point the doubling time was represented
as the inverse of the slope (∆t = 4/(k × L1)) (code available at: https://github.com/
huoww07/calulate_bacteria_doubling_time). To evaluate the goodness of fit,
the R2 value was calculated for each growth curve assay (the R2 ranges from 0 to 1,
representing the worst to the best fit). At least three biological replicates were
performed for each test strain (Supplementary Tables 3 and 4) and the average
doubling time and standard deviation were calculated. Statistical significance was
determined using one-way ANOVA followed by Dunnett’s multiple comparisons
in R 4.1.2.
Statistics, software and visualization. Data analysis and statistics were performed
in GraphPad Prism 9 or R 4.1.2, using packages including tidyverse, knitr and
DescTools. Data visualization was performed using GraphPad Prism 9.
Reporting summary. Further information on research design is available in the
Nature Research Reporting Summary linked to this article.

Data availability

Sequencing reads that support the findings of this study (Fig. 2) are deposited in
the NCBI SRA with the accession code PRJNA485355. Detailed accession numbers
for each sample are listed in Supplementary Table 1. Sequencing reads were
analysed by breseq (https://github.com/barricklab/breseq) and all variants can be
found at https://github.com/huoww07/Ab_evolutionary_pathways. Variants were
filtered against parental WT AB17978 and results are attached as Supplementary
Dataset 2. A. baumannii genome data used in this study (Fig. 5) are available in the
PATRIC database (patricbrc.org) with the sequence IDs listed in Supplementary
Dataset 1. Source data are provided with this paper.

Code availability

All tools are publicly available. MLST analysis was performed using Pasteur
scheme with the publicly available tool ‘mlst’ (https://github.com/tseemann/
mlst). A phylogenetic tree from select 139 genomes was built using mashtree
(https://github.com/lskatz/mashtree). Bacterial doubling time was computed
using customized Python scripts available at https://github.com/huoww07/
calulate_bacteria_doubling_time.
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